Key result
Finerenone reduced cardiovascular and kidney composite risks vs placebo in CKD and T2D regardless of SGLT2i use.
Why the study?
Does finerenone reduce the risk of cardiovascular and kidney composite outcomes in patients with chronic kidney disease and type 2 diabetes irrespective of SGLT2 inhibitor use?
RCT (n=13,026)
Randomly assigned
Does finerenone reduce the risk of cardiovascular and kidney composite outcomes in patients with chronic kidney disease and type 2 diabetes irrespective of SGLT2 inhibitor use?
Answers are grounded in this paper and cite their sources.
Finerenone provides cardiorenal benefits in patients with chronic kidney disease and type 2 diabetes regardless of concomitant SGLT2 inhibitor therapy.
OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) were evaluated in a prespecified pooled analysis of these studies. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g and estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 were randomly assigned to finerenone or placebo; SGLT2is were permitted at any time. Outcomes included cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% eGFR decline, or renal death) end points, changes in UACR and eGFR, and safety outcomes. RESULTS: Among 13,026 patients, 877 (6.7%) received an SGLT2i at baseline and 1,113 (8.5%) initiated one during the trial. For the cardiovascular composite, the hazard ratios (HRs) were 0.87 (95% CI 0.79-0.96) without SGLT2i and 0.67 (95% CI 0.42-1.07) with SGLT2i. For the kidney composite, the HRs were 0.80 (95% CI 0.69-0.92) without SGLT2i and 0.42 (95% CI 0.16-1.08) with SGLT2i. Baseline SGLT2i use did not affect risk reduction for the cardiovascular or kidney composites with finerenone (Pinteraction = 0.46 and 0.29, respectively); neither did SGLT2i use concomitant with study treatment. CONCLUSIONS: Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.
No takes yet. Share an insight, caveat, or question.
Rossing et al. (2022) conducted an RCT in Chronic kidney disease and type 2 diabetes (n=13,026). Finerenone vs. Placebo was evaluated on Cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (HR 0.87 without SGLT2i; HR 0.67 with SGLT2i, 95% CI 0.79-0.96 without SGLT2i; 0.42-1.07 with SGLT2i, p=0.46 (for interaction)). Finerenone reduced cardiovascular and kidney composite risks vs placebo in CKD and T2D regardless of SGLT2i use.
Synapse has enriched 10 related papers. Consider them for comparative context: